« Return to News | CROs/Service Providers

Medpace to undergo equity recapitilization

Tuesday, May 24, 2011 10:51 AM

US-based CRO Medpace will undergo an “equity recapitalization” with affiliates of CCMP Capital Advisors, under which CCMP will end up with an 80% stake in the company while the remaining 20% share will belong to the current Medpace management team, according to Pharma Times.

No financial details were released.

The existing Medpace management will remain in place, as will August Troendle as president and chief executive officer. Medpace will also continue to operate out of Cincinnati, Ohio once the recapitalization is completed.

Medpace’s relationship with CCMP will allow the CRO to “add global operational depth” and to further its reputation as “a company well-known for therapeutic and operational excellence” in conducting phase I-IV clinical studies.

“The transaction will provide resources to make the strategic long-term investments that are needed to advance our leadership position, grow the core business, and expand our global reach,” commented Troendle. 

Medpace has more than 1,000 employees and clinical trial experience in over 40 countries.

As well as phase II-IV development services, the CRO provides phase I/ IIA clinical services through Medpace Clinical Pharmacology; central laboratory and therapeutically specialized testing through Medpace Reference Laboratories; bioanalytical services through Medpace Bioanalytical Laboratories; centralized imaging core laboratory management and reading through Imagepace; and medical device development through Medpace Medical Device.

.

 

Share:          
CLINICAL TRIAL RESOURCES

Search:

NEWS ONLINE ARCHIVE

Browse by:

CWWeekly

September 30

Novartis-Walgreens pilot study blurring the line between retail pharmacy, investigative site

CISCRP to launch traveling science museum exhibit to demystify clinical trial participation

Already a subscriber?
Log in to your digital subscription.

Subscribe to CWWeekly.

The CenterWatch Monthly

October

New growth and decline in Asia clinical trials
South Korea, Japan, China see big growth in 1572s, while India posts huge drop

Harnessing Big Data to transform clinical trials
From protocol to patient recruiting, data analytics can yield valuable insights

Already a subscriber?
Log in to your digital subscription.

Purchase the October issue.

Subscribe to
The CenterWatch Monthly.

The CenterWatch Monthly

September

Sponsors look to collaborate on comparator drugs
Co-therapies, comparators are in 60% of studies, cost $25m per company a year

Early adopters implement risk-based monitoring pilot programs
Experiments aim to offer long-term solutions, despite short-term uncertainties

Already a subscriber?
Log in to your digital subscription.

Purchase the September issue.

Subscribe to
The CenterWatch Monthly.

JobWatch centerwatch.com/jobwatch

Featured Jobs

More Jobs

 

Copyright © 1995-2013 CenterWatch.